1 recruiting, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Hamlet Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Hamlet Pharma AB | 194 | 2026-09-17 | 2026-09-21 |
| A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer alpha1H, 7.4 mg/mL, placebo, alpha1H, 37 mg/mL - Non-muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Hamlet Pharma AB | 52 | 2018-05-21 | 2020-08-19 |
Non-Muscle Invasive Bladder Neoplasms (2) · Urinary Bladder Neoplasms (2) · Neoplasms (1)
Transurethral Resection of Bladder (1)
Czechia (2)
PMID 34103518, PMID 38553868, PMID 42337683
2016 (1)